Reference | Exposure Category | Myeloid leukemia | AML | CML | ||||||
---|---|---|---|---|---|---|---|---|---|---|
No. of cases | Point estimate | 95% CI | No. of cases | Point estimate | 95% CI | No. of cases | Point estimate | 95% CI | ||
Overall Results in Most Informative Cohorts | ||||||||||
Meyers 2013 [29] | Exposed | 21 | 1.28 | 0.79–1.96 | 14 | 1.22 | 0.67–2.05 | 5 | 1.35 | 0.44–3.15 |
Coggon 2014 [30] | Exposed | 36 | 1.20 | 0.84–1.66 | ||||||
Checkoway 2015 [31] | Exposed | 44 | 0.86 | 0.64–1.16 | 30 | 0.80 | 0.56–1.14 | 13 | 0.97 | 0.56–1.67 |
Results of Category at Highest Exposure in Studies | ||||||||||
Beane Freeman 2009 [32] | Peak exposure > 4 ppm | 19 | 1.78 | 0.87–3.64 | ||||||
Checkoway 2015 [31] | Peak exposure > 4 ppm | 10 | 1.80 | 0.85–3.79 | 6 | 1.43 | 0.56–3.63 | 4 | 3.07 | 0.83–11.40 |
Cumulative exposure > 2.5 ppm-yrs | 14 | 0.94 | 0.47–1.86 | 10 | 0.96 | 0.43–2.16 | 4 | 0.92 | 0.25–3.36 | |
Coggon 2014 [30] | High exposure, > one year | 50 | 0.96 | 0.24–3.82 | ||||||
Saberi Hosjineh 2013 [33] | ≥Low exposure | N/A | 1.01 | 0.65–1.57 | N/A | 0.92 | 0.46–1.84 | |||
Meyers 2013 [29] | Duration of exposure 10 + yrs. | 10 | 1.84 | 0.88–3.38 | 7 | 1.81 | 0.73–3.73 | |||
Talibov 2014 [34] | Cumulative exposure > 1.6 ppm-yrs | 424 | 1.17 | 0.91–1.51 |